Belite Bio (BLTE) announced the completion of the last subject visit in the Phase 3 DRAGON clinical trial evaluating Tinlarebant for the treatment of Stargardt disease type 1. Belite Bio expects to report top-line results from the DRAGON trial in Q4 2025 and plans to file New Drug Applications in 1H 2026. “We are very pleased to announce the successful completion of the DRAGON trial. This is an important milestone in our mission to bring a treatment to patients living with Stargardt disease,” said Dr. Tom Lin, Chairman and CEO of Belite Bio. “With no approved therapies available today, Tinlarebant has the potential to be the first treatment for this devastating inherited macular degeneration. We are deeply grateful to the patients, families, investigators, and study teams worldwide who made this clinical trial possible.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio announces up to $250M upsized private placement financing
- Belite Bio Secures $125 Million in PIPE Financing with Potential for More
- Promising Clinical Trials and Strong Financial Position Reinforce Buy Rating for Belite Bio
- Belite Bio’s Tinlarebant: A Promising Investment with Breakthrough Potential for Stargardt Disease
- Belite Bio’s Earnings Call: Progress Amid Challenges